NASDAQ:RARE - Ultragenyx Pharmaceutical Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $143.94
  • Forecasted Upside: 50.74 %
  • Number of Analysts: 14
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 10 Buy Ratings
  • 0 Strong Buy Ratings
▲ +0.57 (0.60%)

This chart shows the closing price for RARE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Ultragenyx Pharmaceutical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RARE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RARE

Analyst Price Target is $143.94
▲ +50.74% Upside Potential
This price target is based on 14 analysts offering 12 month price targets for Ultragenyx Pharmaceutical in the last 3 months. The average price target is $143.94, with a high forecast of $186.00 and a low forecast of $88.00. The average price target represents a 50.74% upside from the last price of $95.49.

This chart shows the closing price for RARE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 14 polled investment analysts is to buy stock in Ultragenyx Pharmaceutical. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 7 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 11 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 11 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 11 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 10 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/9/2021SVB LeerinkInitiated CoverageBuy$178.00High
5/6/2021CitigroupUpgradeNeutral ➝ Buy$160.00 ➝ $151.00High
5/6/2021Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellUpgradeNeutral ➝ Buy$160.00 ➝ $151.00High
5/5/2021Evercore ISIUpgradeIn-Line ➝ Outperform$144.00High
5/5/2021Morgan StanleyLower Price TargetOverweight$170.00 ➝ $156.00Low
4/19/2021Morgan StanleyLower Price TargetOverweight$175.00 ➝ $170.00Medium
3/1/2021Stifel NicolausInitiated CoverageBuy$179.00High
2/16/2021SVB LeerinkBoost Price TargetOutperform$115.00 ➝ $178.00Low
2/12/2021WedbushBoost Price TargetNeutral$113.00 ➝ $130.00Low
2/12/2021Piper SandlerBoost Price TargetOverweight$165.00 ➝ $170.00Low
2/12/2021BarclaysBoost Price TargetOverweight$176.00 ➝ $186.00Low
2/12/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$165.00Low
1/25/2021Credit Suisse GroupBoost Price TargetNeutral$64.00 ➝ $99.00High
1/11/2021Robert W. BairdBoost Price TargetOutperform$110.00 ➝ $165.00Medium
1/11/2021BarclaysBoost Price TargetOverweight$121.00 ➝ $176.00High
12/7/2020WedbushDowngradeOutperform ➝ Neutral$105.00 ➝ $110.00Medium
11/24/2020Evercore ISIReiterated RatingIn-Line$110.00High
11/12/2020Bank of AmericaDowngradeBuy ➝ Neutral$104.00 ➝ $126.00High
10/29/2020Canaccord GenuityBoost Price TargetBuy$92.00 ➝ $105.00High
10/28/2020TruistBoost Price Target$88.00 ➝ $110.00High
10/28/2020WedbushBoost Price TargetOutperform$97.00 ➝ $105.00Low
10/28/2020Morgan StanleyBoost Price TargetOverweight$89.00 ➝ $91.00Low
10/28/2020BarclaysBoost Price TargetOverweight$99.00 ➝ $121.00Medium
10/28/2020SVB LeerinkBoost Price TargetOutperform$110.00 ➝ $115.00Medium
10/27/2020Piper SandlerBoost Price TargetOverweight$83.00 ➝ $108.00Medium
10/15/2020Bank of AmericaBoost Price TargetBuy$93.00 ➝ $107.00Medium
10/13/2020Morgan StanleyBoost Price TargetOverweight$87.00 ➝ $89.00Medium
8/26/2020Canaccord GenuityBoost Price TargetBuy$91.00 ➝ $92.00High
7/31/2020Credit Suisse GroupReiterated RatingHold$64.00Low
7/31/2020Morgan StanleyLower Price TargetOverweight$88.00 ➝ $87.00High
7/31/2020BarclaysBoost Price TargetOverweight$87.00 ➝ $99.00Low
7/28/2020JPMorgan Chase & Co.Reiterated RatingBuy$84.00High
7/15/2020Morgan StanleyBoost Price TargetOverweight$83.00 ➝ $88.00Low
7/2/2020Canaccord GenuityBoost Price TargetBuy$85.00 ➝ $91.00Medium
7/1/2020SunTrust BanksBoost Price Target$82.00 ➝ $88.00Medium
7/1/2020Credit Suisse GroupBoost Price TargetNeutral$60.00 ➝ $64.00High
7/1/2020JPMorgan Chase & Co.Boost Price TargetOverweight$76.00 ➝ $84.00High
7/1/2020WedbushBoost Price TargetHold ➝ Outperform$83.00 ➝ $91.00High
7/1/2020Morgan StanleyBoost Price TargetOverweight$79.00 ➝ $83.00High
7/1/2020Robert W. BairdBoost Price TargetOutperform$75.00 ➝ $90.00High
6/30/2020Piper SandlerBoost Price TargetOverweight$70.00 ➝ $83.00High
6/19/2020SunTrust BanksBoost Price TargetBuy$80.00 ➝ $82.00High
6/19/2020WedbushBoost Price TargetOutperform$73.00 ➝ $83.00High
6/19/2020Canaccord GenuityBoost Price TargetBuy$75.00 ➝ $85.00High
5/18/2020Stifel NicolausBoost Price TargetPositive ➝ Buy$70.00 ➝ $82.00High
5/8/2020CitigroupBoost Price TargetNeutral$53.00 ➝ $66.00Low
4/1/2020Robert W. BairdReiterated RatingBuy$75.00High
2/18/2020Evercore ISIReiterated RatingBuyLow
2/16/2020JPMorgan Chase & Co.Reiterated RatingBuy$76.00Low
2/14/2020WedbushBoost Price TargetOutperform$71.00 ➝ $75.00High
2/14/2020CowenReiterated RatingBuy$75.00High
1/17/2020Morgan StanleyBoost Price TargetOverweight$73.00 ➝ $77.00Low
1/10/2020SunTrust BanksReiterated RatingBuy$75.00 ➝ $80.00High
1/2/2020Raymond JamesDowngradeOutperform ➝ Market PerformHigh
12/18/2019Piper Jaffray CompaniesReiterated RatingBuy$70.00High
12/18/2019CowenReiterated RatingBuy$59.00High
12/17/2019Morgan StanleyLower Price TargetOverweight$76.00 ➝ $73.00Medium
11/6/2019Morgan StanleyLower Price TargetOverweight$79.00 ➝ $76.00High
11/6/2019JPMorgan Chase & Co.Reiterated RatingBuy$75.00High
11/5/2019CowenReiterated RatingBuy$62.00High
9/4/2019Piper Jaffray CompaniesSet Price TargetBuy$75.00Low
9/4/2019JPMorgan Chase & Co.Reiterated RatingBuyLow
9/4/2019SVB LeerinkReiterated RatingOutperform ➝ Positive$80.00 ➝ $85.00High
8/15/2019WedbushReiterated RatingBuy$75.00High
8/15/2019CowenReiterated RatingBuyHigh
8/5/2019JPMorgan Chase & Co.Reiterated RatingBuy$75.00Medium
8/4/2019BarclaysReiterated RatingBuy$87.00Medium
8/2/2019Morgan StanleyLower Price TargetOverweight$83.00 ➝ $79.00High
8/2/2019WedbushReiterated RatingOutperform ➝ Outperform$75.00High
6/17/2019Morgan StanleySet Price TargetBuy$83.00Low
5/9/2019BarclaysReiterated RatingBuyLow
5/7/2019WedbushReiterated RatingOutperform$88.00 ➝ $77.00High
3/27/2019Morgan StanleyUpgradeEqual Weight ➝ Overweight$68.00 ➝ $83.00Medium
2/26/2019CowenReiterated RatingBuy$69.00High
2/22/2019Raymond JamesReiterated RatingOutperform ➝ Outperform$80.00Low
2/21/2019CitigroupBoost Price TargetNeutral ➝ Neutral$54.00 ➝ $62.00High
2/20/2019Credit Suisse GroupReiterated RatingHold$59.00High
1/23/2019SunTrust BanksBoost Price TargetBuy$71.00High
1/7/2019WedbushReiterated RatingOutperform$88.00Medium
1/7/2019CowenReiterated RatingBuyMedium
1/4/2019Credit Suisse GroupSet Price TargetHold$59.00Medium
1/2/2019Raymond JamesDowngradeOutperform ➝ Market PerformMedium
11/15/2018Credit Suisse GroupSet Price TargetHold$59.00High
11/14/2018JPMorgan Chase & Co.Reiterated RatingBuyMedium
11/8/2018CitigroupUpgradeSell ➝ Neutral$46.00 ➝ $54.00N/A
11/7/2018Canaccord GenuityLower Price TargetBuy$90.00 ➝ $75.00Low
11/6/2018Raymond JamesBoost Price TargetOutperform ➝ Buy$53.00 ➝ $57.00Medium
10/29/2018WedbushLower Price TargetOutperform ➝ Outperform$90.00 ➝ $88.00High
10/29/2018CitigroupLower Price TargetSell ➝ Sell$49.00 ➝ $46.00High
10/29/2018Morgan StanleySet Price TargetHold$92.00 ➝ $70.00High
10/29/2018Credit Suisse GroupLower Price TargetNeutral ➝ Hold$78.00 ➝ $59.00High
10/29/2018SunTrust BanksLower Price TargetBuy ➝ Buy$83.00 ➝ $54.00Medium
10/27/2018JPMorgan Chase & Co.Set Price TargetBuy$68.00Medium
10/26/2018Raymond JamesSet Price TargetBuy$70.00Low
10/26/2018Piper Jaffray CompaniesLower Price TargetOverweight$70.00High
10/7/2018JPMorgan Chase & Co.Reiterated RatingBuy$86.00Low
9/11/2018Bank of AmericaBoost Price TargetBuy ➝ Buy$72.00 ➝ $94.00Low
9/10/2018Morgan StanleyReiterated RatingEqual ➝ Equal Weight$92.00Low
9/2/2018JMP SecuritiesReiterated RatingBuy$94.00Medium
8/30/2018WedbushBoost Price TargetOutperform ➝ Outperform$80.00 ➝ $90.00Medium
8/29/2018JPMorgan Chase & Co.Reiterated RatingBuyMedium
8/20/2018SunTrust BanksBoost Price TargetBuy ➝ Positive$83.00Low
8/6/2018WedbushBoost Price TargetOutperform ➝ Outperform$71.00 ➝ $80.00High
8/3/2018Canaccord GenuityBoost Price TargetBuy ➝ Buy$80.00 ➝ $90.00High
8/3/2018Robert W. BairdReiterated RatingBuy$95.00High
8/3/2018BarclaysReiterated RatingOverweight ➝ Overweight$74.00 ➝ $92.00High
8/3/2018Piper Jaffray CompaniesBoost Price TargetOverweight$85.00High
7/17/2018SVB LeerinkBoost Price TargetOutperform ➝ Outperform$68.00 ➝ $95.00Low
6/21/2018Credit Suisse GroupDowngradeOutperform ➝ Neutral$67.00 ➝ $80.00High
5/11/2018BarclaysUpgradeEqual Weight ➝ Overweight$62.00 ➝ $74.00High
5/10/2018The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$63.00Medium
4/18/2018CowenReiterated RatingBuyMedium
4/18/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$74.00 ➝ $77.00High
4/18/2018WedbushReiterated RatingOutperform ➝ Positive$64.00 ➝ $71.00High
4/18/2018JMP SecuritiesBoost Price TargetOutperform$70.00 ➝ $74.00High
4/18/2018SunTrust BanksUpgradeHold ➝ Buy$41.67 ➝ $55.00Low
4/17/2018Bank of AmericaBoost Price Target$61.00 ➝ $72.00Low
3/22/2018Piper Jaffray CompaniesReiterated RatingOverweight ➝ Overweight$67.00Medium
2/23/2018Robert W. BairdReiterated RatingBuy$70.00Medium
2/21/2018Bank of AmericaBoost Price TargetBuy ➝ Buy$60.00 ➝ $61.00High
2/21/2018Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$57.00 ➝ $60.00High
2/21/2018JPMorgan Chase & Co.Reiterated RatingMarket Outperform ➝ Overweight$68.00 ➝ $66.00High
2/21/2018Stifel NicolausReiterated RatingBuy ➝ Buy$85.00 ➝ $74.00High
1/22/2018Evercore ISIUpgradeIn-Line ➝ OutperformHigh
1/17/2018Credit Suisse GroupInitiated CoverageOutperform ➝ Outperform$67.00Low
12/15/2017Raymond JamesReiterated RatingBuyLow
12/5/2017Raymond JamesReiterated RatingBuyMedium
12/5/2017Canaccord GenuitySet Price TargetBuy$80.00Medium
12/5/2017BarclaysBoost Price TargetEqual Weight ➝ Equal Weight$60.00 ➝ $62.00High
12/4/2017Jefferies Financial GroupUpgradeHold ➝ Buy$58.00 ➝ $72.00High
11/16/2017Canaccord GenuitySet Price TargetBuy$83.00 ➝ $80.00N/A
11/15/2017CowenReiterated RatingBuyN/A
11/5/2017JPMorgan Chase & Co.Reiterated RatingBuy$76.00N/A
11/3/2017Robert W. BairdLower Price TargetOutperform$85.00 ➝ $80.00N/A
10/6/2017Morgan StanleyReiterated RatingEqual Weight$69.00 ➝ $71.00N/A
9/19/2017Robert W. BairdReiterated RatingBuyLow
9/14/2017WedbushUpgradeNeutral ➝ Outperform$62.00High
9/12/2017Canaccord GenuityReiterated RatingBuyLow
9/6/2017BarclaysInitiated CoverageEqual Weight$60.00High
8/23/2017Jefferies Financial GroupSet Price TargetHold$62.00Low
8/23/2017JPMorgan Chase & Co.Set Price TargetBuy$87.00 ➝ $76.00Low
8/23/2017JMP SecuritiesLower Price TargetMarket Outperform$90.00 ➝ $80.00Low
8/23/2017Morgan StanleyReiterated RatingEqual Weight$80.00 ➝ $69.00High
8/23/2017Stifel NicolausReiterated RatingBuy$95.00 ➝ $85.00High
8/23/2017SVB LeerinkReiterated RatingOutperform$89.00 ➝ $83.00High
8/23/2017CowenReiterated RatingOutperformHigh
8/23/2017SunTrust BanksDowngradeBuy ➝ Hold$105.00 ➝ $55.00High
8/22/2017Canaccord GenuityReiterated RatingBuy$98.00 ➝ $83.00High
8/16/2017Evercore ISIInitiated CoverageIn ➝ In-Line$63.00High
8/8/2017HC WainwrightReiterated RatingNeutral ➝ Neutral$72.00 ➝ $75.00Low
7/28/2017Canaccord GenuitySet Price TargetBuy$98.00Low
7/27/2017Sanford C. BernsteinInitiated CoverageMarket Perform$72.00High
7/14/2017Jefferies Financial GroupReiterated RatingHold$68.00High
6/30/2017Stifel NicolausReiterated RatingBuy$111.00Low
6/29/2017CowenReiterated RatingOutperformLow
5/8/2017Canaccord GenuityReiterated RatingBuyLow
5/8/2017Morgan StanleyLower Price TargetEqual Weight$84.00 ➝ $79.00Low
5/8/2017Jefferies Financial GroupBoost Price TargetHold$66.00 ➝ $68.00Low
4/19/2017Robert W. BairdReiterated RatingOutperform$90.00Medium
4/19/2017CowenReiterated RatingOutperformMedium
4/19/2017SunTrust BanksBoost Price TargetBuy$100.00 ➝ $105.00Medium
4/19/2017Canaccord GenuityReiterated RatingBuy$100.00High
4/19/2017WedbushDowngradeOutperform ➝ Neutral$80.00 ➝ $75.00High
4/19/2017HC WainwrightDowngradeBuy ➝ Neutral$88.00 ➝ $72.00High
4/6/2017Jefferies Financial GroupDowngradeBuy ➝ Hold$109.00 ➝ $66.00High
3/23/2017HC WainwrightReiterated RatingBuyHigh
3/23/2017CowenReiterated RatingBuyHigh
3/23/2017Canaccord GenuityReiterated RatingBuy$100.00Medium
3/23/2017Piper Jaffray CompaniesReiterated RatingOverweight ➝ NeutralHigh
3/23/2017WedbushLower Price TargetBuy$88.00 ➝ $80.00High
3/22/2017Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$96.00 ➝ $70.00High
2/17/2017CowenReiterated RatingBuyN/A
2/17/2017WedbushInitiated CoverageOutperform$88.00N/A
2/17/2017Jefferies Financial GroupReiterated RatingBuy$109.00N/A
11/30/2016CitigroupDowngradeNeutral ➝ SellN/A
11/30/2016WedbushReiterated RatingOutperform$92.00N/A
11/30/2016Piper Jaffray CompaniesReiterated RatingBuy$96.00N/A
11/14/2016Jefferies Financial GroupSet Price TargetBuy$109.00N/A
11/14/2016SVB LeerinkReiterated RatingOutperform$94.00 ➝ $90.00N/A
11/14/2016CitigroupDowngradeNeutral ➝ Sell$66.00 ➝ $64.00N/A
11/11/2016Canaccord GenuitySet Price TargetBuy$103.00N/A
11/9/2016JPMorgan Chase & Co.Reiterated RatingBuy$106.00N/A
11/8/2016Piper Jaffray CompaniesReiterated RatingBuy$79.00N/A
11/8/2016WedbushReiterated RatingOutperform$92.00N/A
10/21/2016Canaccord GenuitySet Price TargetBuy$120.00N/A
9/25/2016HC WainwrightReiterated RatingBuy$102.00 ➝ $109.00N/A
9/20/2016Canaccord GenuitySet Price TargetBuy$120.00N/A
9/20/2016SVB LeerinkReiterated RatingOutperform$85.00 ➝ $94.00N/A
9/19/2016WedbushReiterated RatingOutperform$92.00N/A
9/18/2016Jefferies Financial GroupSet Price TargetBuy$109.00N/A
9/14/2016Credit Suisse GroupReiterated RatingBuy$101.00N/A
9/12/2016Jefferies Financial GroupSet Price TargetBuy$109.00N/A
8/25/2016SVB LeerinkReiterated RatingBuy$86.00N/A
8/9/2016CowenReiterated RatingBuyN/A
8/9/2016Piper Jaffray CompaniesSet Price TargetBuy$70.00 ➝ $82.00N/A
8/9/2016Credit Suisse GroupReiterated RatingBuy$101.00N/A
8/9/2016WedbushReiterated RatingOutperform$92.00N/A
8/8/2016JPMorgan Chase & Co.Set Price TargetBuy$110.00N/A
8/1/2016Jefferies Financial GroupSet Price TargetBuy$109.00N/A
7/18/2016Robert W. BairdReiterated RatingOutperform$85.00N/A
7/17/2016Jefferies Financial GroupReiterated RatingBuyN/A
7/17/2016Piper Jaffray CompaniesReiterated RatingOverweight$70.00N/A
7/15/2016CowenReiterated RatingBuyN/A
7/15/2016SVB LeerinkReiterated RatingBuy$85.00N/A
7/15/2016Canaccord GenuityReiterated RatingBuy$120.00N/A
7/12/2016Credit Suisse GroupReiterated RatingBuyN/A
7/7/2016Piper Jaffray CompaniesInitiated CoverageOverweight$70.00N/A
6/28/2016WedbushReiterated RatingOutperform$92.00N/A
6/28/2016Bank of AmericaInitiated CoverageBuy$72.00N/A
(Data available from 6/21/2016 forward)
Ultragenyx Pharmaceutical logo
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; and Dojolvi for treating long-chain fatty acid oxidation disorders. The company is also developing DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy product candidate for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
Read More

Today's Range

Now: $95.49
Low: $93.56
High: $96.77

50 Day Range

MA: $105.14
Low: $92.19
High: $115.71

52 Week Range

Now: $95.49
Low: $72.43
High: $179.65


993,471 shs

Average Volume

465,694 shs

Market Capitalization

$6.44 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Ultragenyx Pharmaceutical?

The following equities research analysts have issued reports on Ultragenyx Pharmaceutical in the last twelve months: Bank of America Co., Barclays PLC, Canaccord Genuity, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Credit Suisse Group AG, Evercore ISI, JPMorgan Chase & Co., Morgan Stanley, Piper Sandler, Robert W. Baird, Stifel Nicolaus, SunTrust Banks, Inc., SVB Leerink LLC, TheStreet, Truist, Wedbush, and Zacks Investment Research.
View the latest analyst ratings for RARE.

What is the current price target for Ultragenyx Pharmaceutical?

16 Wall Street analysts have set twelve-month price targets for Ultragenyx Pharmaceutical in the last year. Their average twelve-month price target is $143.94, suggesting a possible upside of 50.5%. Barclays PLC has the highest price target set, predicting RARE will reach $186.00 in the next twelve months. SunTrust Banks, Inc. has the lowest price target set, forecasting a price of $88.00 for Ultragenyx Pharmaceutical in the next year.
View the latest price targets for RARE.

What is the current consensus analyst rating for Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical currently has 4 hold ratings and 10 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RARE will outperform the market and that investors should add to their positions of Ultragenyx Pharmaceutical.
View the latest ratings for RARE.

What other companies compete with Ultragenyx Pharmaceutical?

How do I contact Ultragenyx Pharmaceutical's investor relations team?

Ultragenyx Pharmaceutical's physical mailing address is 60 Leveroni Court, Novato CA, 94949. The biopharmaceutical company's listed phone number is 415-483-8800 and its investor relations email address is [email protected] The official website for Ultragenyx Pharmaceutical is